TY  - JOUR

T1  - Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

JO  - J Clin Oncol

PY  - 2009/04/01

AU  - Dean E

AU  - Jodrell D

AU  - Connolly K

AU  - Danson S

AU  - Jolivet J

AU  - Durkin J

AU  - Morris S

AU  - Jowle D

AU  - Ward T

AU  - Cummings J

AU  - Dickinson G et al

ED  - 

DO  - DOI: 10.1200/JCO.2008.19.5677

VL  - 27

IS  - 10

SP  - 1660

EP  - 1666

Y2  - 2024/12/26

ER  -